scholarly journals Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity

2015 ◽  
Vol 23 (10) ◽  
pp. 1653-1662 ◽  
Author(s):  
Daniel O Villarreal ◽  
Megan C Wise ◽  
Rebekah J Siefert ◽  
Jian Yan ◽  
Laurence M Wood ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 515
Author(s):  
Sungmin Jung ◽  
Jea-Hyun Baek

T cell factor 1 (TCF1) is a transcription factor that has been highlighted to play a critical role in the promotion of T cell proliferation and maintenance of cell stemness in the embryonic and CD8+ T cell populations. The regulatory nature of TCF1 in CD8+ T cells is of great significance, especially within the context of T cell exhaustion, which is linked to the tumor and viral escape in pathological contexts. Indeed, inhibitory signals, such as programmed cell death 1 (PD-1) and cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4), expressed on exhausted T lymphocytes (TEX), have become major therapeutic targets in immune checkpoint blockade (ICB) therapy. The significance of TCF1 in the sustenance of CTL-mediated immunity against pathogens and tumors, as well as its recently observed necessity for an effective anti-tumor immune response in ICB therapy, presents TCF1 as a potentially significant biomarker and/or therapeutic target for overcoming CD8+ T cell exhaustion and resistance to ICB therapy. In this review, we aim to outline the recent findings on the role of TCF1 in T cell development and discuss its implications in anti-tumor immunity.


2020 ◽  
Author(s):  
Selma Bekri ◽  
Reunet Rodney-Sandy ◽  
Diana Gruenstein ◽  
Bjarne Bogen ◽  
Daniel Levey ◽  
...  

2020 ◽  
Vol 295 (1) ◽  
pp. 203-219 ◽  
Author(s):  
William J. Turbitt ◽  
Claire Buchta Rosean ◽  
K. Scott Weber ◽  
Lyse A. Norian

2019 ◽  
Vol 7 (7) ◽  
pp. 1202-1213 ◽  
Author(s):  
Emma Reeves ◽  
Oliver Wood ◽  
Christian H. Ottensmeier ◽  
Emma V. King ◽  
Gareth J. Thomas ◽  
...  

2014 ◽  
Vol 173 ◽  
pp. 158-165 ◽  
Author(s):  
Ying-Chyi Song ◽  
Han-Yin Cheng ◽  
Chih-Hsiang Leng ◽  
Sheng-Kuo Chiang ◽  
Chih-Wei Lin ◽  
...  

2017 ◽  
Author(s):  
Helen Loo Yau ◽  
Ankur Chakravarthy ◽  
Felipe Campos de Almeida ◽  
David Allard ◽  
Rajat Singhania ◽  
...  

AbstractRecent studies have shown that DNA methyltransferase inhibitors (DNMTi) can induce IRF7 activation and Type I/III interferon signaling through dsRNA-mediated viral mimicry in cancer cells. By performing a large pan-cancer analysis using TCGA data, we determined that IRF7 activation is associated with higher CD8+ T cell tumor infiltration and higher cytolytic activity across multiple cancer types. Accordingly, we demonstrate that DNMTi treatment results in increased CD8+ T cell tumor infiltration, enhanced cytolytic activity and CD8+ T cell dependent tumor growth inhibition. Finally, we show that DNMTi triggers a process marked by the induction of viral mimicry directly on CD8+ T cells, leading to activation of dsRNA sensing pathway, and up-regulation of T cell activation markers, effector cytokines, and Granzyme B. Taken together, our findings suggest that dsRNA sensing pathway activation in the immune compartment, through pharmacological DNA demethylation, is a viable strategy for boosting anti-tumor immune response.


Sign in / Sign up

Export Citation Format

Share Document